Table 4. Comparison of in-hospital, 1-month, and 1-year clinical outcomes between two groups.
| Outcome | Tacrolimus (n = 151) | Control (n = 165) | Odds ratio (95% CI) | p value |
| In-hospital outcome | ||||
| NYHA functional class, mean ± SD | 1.29 ± 1.13 | 1.31 ± 1.10 | 0.98 (0.80-1.20) | 0.845 |
| Pulmonary edema, % (n) | 9.9% (15) | 12.7% (21) | 0.76 (0.38-1.53) | 0.436 |
| Sepsis, % (n) | 4.6% (7) | 4.2% (7) | 1.01 (0.38-3.20) | 0.865 |
| Stroke, % (n) | 0.0% (0) | 0.0% (0) | -- | -- |
| Recurrent MI, % (n) | 0.0% (0) | 0.0% (0) | -- | -- |
| Staged PCI, % (n) | 30.5% (46) | 23.6% (39) | 1.42 (0.86-2.33) | 0.172 |
| Length of hospital stay (days), mean ± SD | 6.33 ± 3.80 | 6.98 ± 6.30 | 0.98 (0.93-1.02) | 0.282 |
| 1-month outcomes | ||||
| MACCE, % (n) | 3.3% (5) | 4.8% (8) | 0.67 (0.22-2.10) | 0.494 |
| Death | 2.0% (3) | 2.4% (4) | 0.81 (0.18-3.68) | 0.786 |
| Recurrent acute MI | 0% (0) | 0% (0) | -- | -- |
| Stroke | 0.0% (0) | 0.0% (0) | -- | -- |
| Re-hospitalization for ADHF | 2.0% (3) | 3.0% (5) | 0.65 (0.15-2.75) | 0.552 |
| 1-year outcomes | ||||
| MACCE, % (n) | 11.3% (17) | 11.5% (19) | 0.98 (0.49-1.95) | 0.943 |
| Death | 2.6% (4) | 4.3% (7) | 0.61 (0.18-2.13) | 0.438 |
| Recurrent acute MI | 4.7% (7) | 2.5% (4) | 1.94 (0.56-6.75) | 0.300 |
| Stroke | 0.7% (1) | 0.6% (1) | 1.08 (0.07-17.45) | 0.956 |
| Re-hospitalization for ADHF | 4.1% (6) | 5.0% (8) | 0.80 (0.27-2.37) | 0.691 |
| Staged PCI, % (n) | 22.8% (34) | 17.4% (28) | 1.40 (0.80-2.46) | 0.234 |
| CABG surgery, % (n) | 0.7% (1) | 0.0% (0) | -- | 1.000 |
| Hospitalization for infection, % (n) | 2.2% (2) | 2.0% (2) | 1.11 (0.15-8.05) | 0.917 |
Data are expressed as mean ± standard deviation (SD) or % (n).
ADHF, acute decompensated heart failure; CABG, coronary artery bypass grafting; CI, confidence interval; MACCE, major adverse cardiovascular and cerebral vascular events; MI, myocardial infarction; NYHA Fc, New York Heart Association functional class; PCI, percutaneous coronary intervention.